TODAY’S NEWS Big news on the leukemia front: Novartis' Tasigna gets priority FDA review for newly-diagnosed patients; and Roche/Genentech's Rituxan approved for CLL. A quarter of new prescriptions …
Clarity fuel
TODAY’S NEWS Big news on the leukemia front: Novartis' Tasigna gets priority FDA review for newly-diagnosed patients; and Roche/Genentech's Rituxan approved for CLL. A quarter of new prescriptions …